Speakers

Expand/Collapse

Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics

Day Two

Friday October 1, 2021

4:45 pm | BiCKI: An Optimized Anti-PD1 Bispecific Platform In Particular For Immunocytokine Such As With IL-7.

Nimish Gera
Head of Biologics
Mythic Therapeutics

Markus Zettl
Director Immunooncology
Pieris Pharmaceuticals

Pre-Conference Focus Day

2:00 pm | Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific

Kelly Fahnoe
Associate Director – Protein Science
Q32 Bio

Track A - Day 3PM

4:40 pm | Tissue Localized Inhibition of Complement Activation

Yanjing Li
Senior Scientist - Cell Line Development / CMC Lead
Boan Boston

Track B - Day 2

2:15 pm | Cell Line Development Strategies To Improve The Purity Of CD3 Bispecific Antibodies

Carston Wegner
Professor of Medicinal Chemistry
University of Minnesota

Day One

Thursday September 30, 2021

7:45 am | Opening Remarks

Julie Bailis
Director of Research
Amgen

Suzanne Schubbert
Group leader Cell Biology
Xencor

Day Two

Friday October 1, 2021

9:10 am | Panel Discussion: Targeting Checkpoint Inhibitors – PD-1/PD-L1

9:00 am | Chair led Speaker Q&A

8:10 am | CD5 x TGFbR2 Bispecific Antibodies Provide A Novel Strategy To Suppress TGFb By Selective Blockade Of TGFbR2 On T cells

Laura Codarri Deak
Principal Scientist Cancer Immunotherapy
Roche

Day Two

Friday October 1, 2021

9:10 am | Panel Discussion: Targeting Checkpoint Inhibitors – PD-1/PD-L1

9:00 am | Chair led Speaker Q&A

8:35 am | A Novel Bispecific Checkpoint Inhibitor Antibody To Preferentially Block PD-1 And LAG-3 On TILs Whilst Sparing Treg Activation

Bradley Sumrow
Senior Director - Clinical Research & Development
MacroGenics, Inc.

Day Two

Friday October 1, 2021

9:55 am | PD-1-engaging Bispecific DART® molecules: Early Clinical Data Highlights Antitumor & Pharmacodynamic Activity

9:10 am | Panel Discussion: Targeting Checkpoint Inhibitors – PD-1/PD-L1

Chad May
Senior Vice President, R&D
Maverick Therapeutics

Track A - Day 2

1:45 pm | Protease Dependent COBRA Activity Regresses Established Solid Tumors in Mice

Katherine Harris
Vice President, Discovery
TeneoBio

Day Two

Friday October 1, 2021

5:45 pm | A Bispecific Antibody Agonist Of The IL-2 Heterodimeric Receptor Promotes In Vivo Expansion Of CD8 And NK Cells

Matthew Bernett
Director of Protein Engineering
Xencor

Day Two

Friday October 1, 2021

5:15 pm | Xencor’s Pipeline Of Novel Cytokine Fc-Fusions Engineered For Improved Exposure, Selectivity, And Tolerability

Stanislas Blein
Chief Scientific Officer
Ichnos Sciences

Eric Vivier
Chief Scientific Officer
Innate Pharma

Track A - Day 2

11:30 am | Modulating Cancer Immunity with Tri-specific & Multi-Specific Antibodies

Matthew Chun
Senior Scientist
Amgen

Track A - Day 1 AM

12:00 pm | Next Generation Engineering Approaches For Bispecific T Cell Engager (Bite®) Molecules

Anthony Stein
Director, Leukemia Program Codirector
Gehr Family Center for Leukemia Research, City of Hope

Track B - Day 1 3pm

5:40 pm | Overcoming On-Target Off-Tumor Toxicities of Bispecifics

Koustubh Ranade
Head of Translational Medicine
Immunocore

Track B - Day 1 AM

12:00 pm | Tumor Micro-Environment Features Associated With Response To Tebentafusp, A Gp100-Targeted T Cell Receptor-CD3 Bispecific

Ryan Potts
Executive Director & Head of IPP
Amgen

Day Two

Friday October 1, 2021

4:15 pm | Small Molecule Bispecifics For Targeted Protein Degradation

Eva Hansbauer
Associate Director of Protein Analytics
Pieris Pharmaceuticals

Day One

Thursday September 30, 2021

9:20 am | Combining Building Blocks To Bispecifics

Adam Chervin
Principal Research Scientist II
Abbvie

Pre-Conference Focus Day

11:10 am | ABBV-184: A Novel Survivin-Specific T Cell Receptor/CD3 Bispecific Therapeutic For Treatment Of Both Solid Tumor And Hematological Malignancies

Oren Bogin
Chief Executive Officer
Immunorizon

Pre-Conference Focus Day

2:30 pm | Closing Remarks from Chair

11:00 am | Open Address from Chair

Angus Sinclair
VP Immunooncology Research
IGM Biosciences

Track B - Day 1 PM

2:30 pm | IGM-2323 Is A High Avidity Igm-Based CD20xCD3 Bispecific Antibody For Enhanced T-Cell Dependent Killing With Minimal Cytokine Release

Wim van Schooten
Chief Scientific Officer
TeneoBio

Track A - Day 3PM

5:10 pm | Bispecific antibodies for infectious and metabolic diseases

Li Zhou
VP Cell Therapy & Antibody Research
Boan Boston

Track A - Day 2

2:15 pm | Optimization Of Bispecific T Cell Engager With Reduced Cytokine Release

Xiaotian Zhong
Senior Principal Scientist & Laboratory Head
Pfizer

Day One

Thursday September 30, 2021

10:25 am | Panel Discussion: Strategies To Improve The Developability Of Novel Bispecific Antibodies

Track A - Day 2

12:00 pm | Multispecific Biotherapeutics Beyond Immune Cell Engagers

Victoria Smith
Chief Scientific Officer
Amphivena Therapeutics

Track B - Day 1 AM

11:30 am | ReSTORE T Cell Engagers: Maintaining Immune Activation and Controlling CRS via Depletion of MDSC

Sara Mangsbo
Associate senior lecturer, and Co-founder
Uppsala University, Strike pharma AB

Day Two

Friday October 1, 2021

3:45 pm | A Bispecific Antibody Targeting CD40 For Optimized Synthetic Peptide Delivery To Antigen-Presenting Cells

Paolo Meoni
Project Head
Sanofi

Genevive Hernandez
Director of Clinical Biomarkers
IGM Biosciences

Track A - Day 1 PM

2:00 pm | Bispecific T Cell Engagers: Biomarkers of Synthetic Immunity for Cancer Immunotherapy

Paul Moore
VP Immunology & Cell Biology
MacroGenics

Track A - Day 1 PM

2:30 pm | Translational Biomarker Strategies Supporting Clinical Stage Bi-specific DART® Molecules

Mark Chiu
President
Tavotek Therapeutics

Track B - Day 1 PM

1:30 pm | Novel Bispecific EGFR/Met Antibody To Combat Resistance To EGFR Inhibition

Marta Germani
Research Analyst
Beacon Targeted Therapies

Day One

Thursday September 30, 2021

7:55 am | Review Of The Clinical Development Landscape For Bispecifics

Teemu Junttila
Principal Scientist - Translational Oncology Genentech
Genentech

Track B - Day 1 3pm

4:40 pm | A Biological Rationale For Toxicity Mitigation With CD3 Bispecifics

Martin Schroeder
Chief Technology Officer
GT Biopharma

Pre-Conference Focus Day

1:00 pm | TriKE Directed Cell Serial Killing Of Tumor Cells

Jeffrey Miller
Chief Scientific Officer
GT Biopharma

Mohamed Elmeliegy
Associate Director - Clinical Pharmacology
Pfizer

Track B - Day 1 3pm

5:10 pm | An Industry Perspective on CD3 Bispecifics Starting Doses & Efficacious Dose Projections

Walter Ferlin
Chief Scientific Officer
Light Chain Bioscience – Novimmune SA

Pre-Conference Focus Day

1:30 pm | Remodeling Tumor Macrophages With CD47-Targeted Bispecific Antibodies

Bryan Lemon
Director Protein Sciences
Harpoon Therapeutics

Day One

Thursday September 30, 2021

10:25 am | Panel Discussion: Strategies To Improve The Developability Of Novel Bispecific Antibodies

Track B - Day 2

11:00 am | TriTAC: A T Cell Engager Platform Optimized To Treat Solid Tumors

Regis Cebe
Principal Scientist II
Novartis Biologic Center, NIBR Novartis Pharma AG

Day One

Thursday September 30, 2021

3:30 pm | Panel discussion: Reducing The Risk Of Immunogenicity For Bispecifics

8:20 am | Enhancing Quality By Design For Bispecific Molecules

Liat Dassa
Senior Director, Head of R&D
Immunorizon

Track A - Day 2

12:30 pm | Conditional Tumor-Restricted Activation of Multi-specific-Cell Engagers

Yves Poitevin
Head of Bioprossessing
Light Chain Bioscience – Novimmune SA

Track B - Day 2

1:45 pm | Scaling Up A Cost-effective kl-bodyä Purification Process For Phase I Clinical Applicatio

Jonathan Davis
Head of Innovation
Invenra

Day Two

Friday October 1, 2021

3:15 pm | Preclinical Development of a Bispecific Antibody for Neuroblastoma with Improved Efficacy and Reduced Pain

Jane Gross
Chief Scientific Officer
Aptevo Therapeutics

Day One

Thursday September 30, 2021

3:30 pm | Panel discussion: Reducing The Risk Of Immunogenicity For Bispecifics

Track B - Day 1 PM

2:00 pm | Use Of ADAPTIRTM And ADAPTIR-FLEX Platformtm Technologies To Generate Immuno-Modulatory Bispecific Therapeutic Candidates For The Treatment Of Hematologic And Solid Tumors

Nelly Kirklin
VP Immunology
Compass Therapeutics

Day Two

Friday October 1, 2021

9:10 am | Panel Discussion: Targeting Checkpoint Inhibitors – PD-1/PD-L1

Erin Meermeier
Senior Research Fellow
Mayo Clinic

Pre-Conference Focus Day

11:40 am | Preclinical Evaluation Of Murine BCMA x CD3 Bispecific Immunotherapy In Vk*MYC Multiple Myeloma

Umesh Muchhal
Senior Director Protein Sciences
Xencor

Track B - Day 2

12:30 pm | This Track has now come to a close please join us after lunch for the next set of presentations

11:30 am | A Robust And Modular Heterodimeric Fc Platform Engineered For Efficient Development Of Bispecific And Fc Fusion Therapeutics

Tatiana Novobrantseva
Chief Scientific Officer
Verseau Therapeutics

Day One

Thursday September 30, 2021

3:30 pm | Panel discussion: Reducing The Risk Of Immunogenicity For Bispecifics

Samuel Pine
Head of Bioanalysis & Immunogenicity
Ablynx

Day One

Thursday September 30, 2021

3:30 pm | Panel discussion: Reducing The Risk Of Immunogenicity For Bispecifics

Amy Que
Chief Technology Officer
Harbour Biomed

Track B - Day 2

12:30 pm | This Track has now come to a close please join us after lunch for the next set of presentations

12:00 pm | CMC Development of Therapeutic Bispecific Antibodies Generated By Harbour HBICE Platform

Eugene Zhukovsky
Chief Technology Officer
Go Therapeutics

Day One

Thursday September 30, 2021

10:25 am | Panel Discussion: Strategies To Improve The Developability Of Novel Bispecific Antibodies

Darshana Jani
Director, Global Bioanalysis
Agenus inc

Day One

Thursday September 30, 2021

3:30 pm | Panel discussion: Reducing The Risk Of Immunogenicity For Bispecifics

Track A - Day 1 PM

1:30 pm | Bioanalytical Strategies for Bispecific Antibodies During Clinical Development

Yanchen Zhou
Sr. Scientist, Clinical Immunology, Translational Medicine
Amgen, Inc.

Track A - Day 1 PM

3:00 pm | Immunogenicity Assessment for Multi-Functional Biotherapeutics

Giorgio Salciarini
Technical Business Development Manager
BSP Pharmaceuticals

Tony Polverino
Executive Vice President, Early Development and Chief Scientific Officer
Zymeworks

Track A - Day 2

11:00 am | Developing Next-Generation CD3-Engaging Multispecifics Through Tumor- Specific Activation and Checkpoint Modulation

Alison Betts
Vice President of Scientific Collaborations and Fellow of Modeling & Simulation
Applied Biomath

Day One

Thursday September 30, 2021

8:50 am | Mechanistic Strategies for Modeling Avidity: Application in the Design of Tumor Selective Bispecific Antibodies in Oncology

Christel Iffland
Vice President- Antibody Technology
Ligand Pharmaceuticals